Abstract
The rapid expansion in the past two decades in the understanding of the molecular basis of a large variety of novel congenital immunodeficiencies has provided valuable information on the signal transduction general mechanisms, that goes far beyond the comprehension of the individual disease. In most cases, the altered molecules are exclusively expressed in haematopoietic cells, while in other cases they are not restricted to a certain cell type. This leads to more complex clinical phenotypes, which contribute to unravel previously unappreciated non-haematopoietic functions of signaling proteins and the mechanism of coordination and integration of several pathways. Moreover, this knowledge will help define potential new therapeutic strategies through novel molecular targets, drive stem cell development into the desired differentiation path and ameliorate our comprehension of tissue engineering. This review focuses on the multiple roles in haematopoietic and non-haematopoietic receptors of the gamma signaling element with a special attention paid to the participation of gamma to growth hormone receptor signaling, confirming the presence of an interplay between endocrine and immune system.
Keywords: Congenital immunodeficiencies, growth hormone receptor, signal transduction, gamma chain, STATs
Current Signal Transduction Therapy
Title: Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain
Volume: 3 Issue: 3
Author(s): Claudio Pignata, Stefania Amorosi, Ilaria Russo, Donatella Capalbo, Teresa Lettiero, Marsilio Adriani and Mariacarolina Salerno
Affiliation:
Keywords: Congenital immunodeficiencies, growth hormone receptor, signal transduction, gamma chain, STATs
Abstract: The rapid expansion in the past two decades in the understanding of the molecular basis of a large variety of novel congenital immunodeficiencies has provided valuable information on the signal transduction general mechanisms, that goes far beyond the comprehension of the individual disease. In most cases, the altered molecules are exclusively expressed in haematopoietic cells, while in other cases they are not restricted to a certain cell type. This leads to more complex clinical phenotypes, which contribute to unravel previously unappreciated non-haematopoietic functions of signaling proteins and the mechanism of coordination and integration of several pathways. Moreover, this knowledge will help define potential new therapeutic strategies through novel molecular targets, drive stem cell development into the desired differentiation path and ameliorate our comprehension of tissue engineering. This review focuses on the multiple roles in haematopoietic and non-haematopoietic receptors of the gamma signaling element with a special attention paid to the participation of gamma to growth hormone receptor signaling, confirming the presence of an interplay between endocrine and immune system.
Export Options
About this article
Cite this article as:
Pignata Claudio, Amorosi Stefania, Russo Ilaria, Capalbo Donatella, Lettiero Teresa, Adriani Marsilio and Salerno Mariacarolina, Shared Signaling Pathways Between Endocrine and Immune System Receptors: The Model of Gamma Chain, Current Signal Transduction Therapy 2008; 3 (3) . https://dx.doi.org/10.2174/157436208785699695
DOI https://dx.doi.org/10.2174/157436208785699695 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design The Design of Experiment Approach, Rheology for Optimization of a Topical Anti-inflammatory and Analgesic Cream
Current Drug Delivery Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors
Current Medicinal Chemistry Meet Our Editor-in-Chief
Clinical Cancer Drugs Exploring the Nucleolar Proteome: Novel Concepts for Chaperone Trafficking and Function
Current Proteomics Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Inhibitors of Sialyltransferases: Potential Roles in Tumor Growth and Metastasis
Mini-Reviews in Medicinal Chemistry Bioactive Flavonoids from Cornus mas L. Fruits
Mini-Reviews in Organic Chemistry Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging Do Folate, Vitamins B<sub>6</sub> and B<sub>12</sub> Play a Role in the Pathogenesis of Migraine? The Role of Pharmacoepigenomics
CNS & Neurological Disorders - Drug Targets Biomarkers, Critical Disease Pathways, Drug Targets, and Alternative Medicine in Male Breast Cancer
Current Drug Targets Phosphatidylinositol 3-kinase Glu545Lys and His1047Tyr Mutations are not Associated with T2D
Current Diabetes Reviews Editorial: Plant Derived Secondary Metabolites as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Quinone Methides as DNA Alkylating Agents: An Overview on Efficient Activation Protocols for Enhanced Target Selectivity
Current Organic Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets